In this issue Matsumoto et al (2001) report the 10 year survival rates of a randomized placebo-controlled trial in which colorectal cancer patients received cimetidine and oral 5-fluorouracil (5-FU) or 5-FU alone as an adjuvant therapy following curative resection. In this small study a highly significant improvement in survival is demonstrated most notably in patients with node-positive (Dukes C) tumours (10 year survival – 85%). A further retrospective analysis suggests that this appeared to be due to a remarkable effect of cimetidine on patients with tumours expressing the sialyl Lewis adhesion epitopes X and A (sLx and sLA).
The histamine type 2 (H2) receptor antagonist cimetidine was first proposed as an anti-cancer agent in 1979 (Armitage and Sidner, 1979). This followed the spontaneous remission of two patients with metastatic carcinoma after coincidental use of the drug. Since then there have been several clinical trials assessing cimetidine in a range of malignancies with varied and inconclusive results.
In 1988 it was reported that post-operative treatment with cimetidine improved survival in gastric cancer patients of all stages (increasing median survival from 316 to 459 days) (Tonnesen et al, 1988). However, in a more recent and larger study organized by the British Stomach Cancer Group, cimetidine had no effect on survival when compared to placebo (Langman et al, 1999). Trials combining cimetidine with immunotherapy approaches in renal cell carcinoma and melanoma have also failed to demonstrate any benefit to the addition of cimetidine (Creagan et al, 1985; Sagaster et al, 1995).
Results have been more promising using cimetidine in colorectal cancer. In addition to the study in this issue (which was first reported in 1995; Matsumoto, 1995), there are now three other studies that have shown non-significant trends to improved survival. In 1994 Adams and Morris reported that a 7 day perioperative course of cimetidine improved 3-year survival from 59 to 93% (P=0.17) in 34 colorectal cancer patients (Adams and Morris, 1994). In a more recent study of 125 patients by the same group this regime showed a similar trend that achieved significance in patients with tumours negative for microsatellite instability (Kelly et al, 1999). In a randomized study of 192 patients, Svendsen et al (1995) also showed a trend to improved survival in Dukes C patients. In addition to these studies of adjuvant cimetidine, a small trial compared 5-FU-based chemotherapy alone or in combination with cimetidine in patients with advance disease (Links et al, 1995). Although no difference in overall response was seen there was a significantly increased rate of CEA response (>50% reduction compared with baseline) in the cimetidine group.
The exact mechanism by which cimetidine may exert an anti-cancer effect remains uncertain. High concentrations of histamine are known to occur in colorectal cancer tissues (Garcia-Caballero et al, 1993). Histamine stimulates the in vivo growth of experimental colorectal tumours and cimetidine can inhibit this effect (Adams et al, 1994a). However, other, far more potent H2 receptor antagonists such as ranitidine do not show the same effect either in vitro (Lawson et al, 1996), or in large clinical trials (Nielsen et al, 1998). This suggests that either the H2 receptor on tumour cells is structurally distinct from those found on parietal cells, or that the mechanism of action my be independent of classical H2 receptor antagonism.
Cimetidine has also been shown to have a number of immunomodulatory effect. Histamine negatively regulates T helper (TH1 and TH2) cell responses through the H2 receptor and H2 receptor knockout mice show upregulation of TH1 and TH2 cytokines (Jutel et al, 2001). Increased release of histamine has been proposed as the cause of the immunosuppression seen at the time of colonic resection and several studies have shown that perioperative H2 receptor antagonists can prevent this effect, thereby improving immune surveillance at the time of surgery (Adams et al, 1994b). The presence of tumour infiltrating lymphocytes (TIL) within rectal tumour tissues is considered to be an independent pathological marker of good prognosis (Harrison et al, 1994). Early clinical studies suggested that perioperative treatment with cimetidine resulted in an increased peritumoural lymphocyte infiltration (Adams and Morris, 1994, 1997). A more recent trial however, has failed to confirm this with the subgroup of patients appearing to benefit most from cimetidine being the aggressive tumours that lacked TILs (Kelly et al, 1999).
Recently Kobayashi et al (2000) have proposed a novel mechanism of action. They showed that cimetidine could block the adhesion of a colorectal tumour cell line to endothelial cells in vitro and could suppress the formation of hepatic metastases in a nude mouse model, via the down regulation of cell surface expression of the adhesion molecule E-selectin on endothelial cells.
E-selectin (or ELAM-1) is a member of the selectin family of adhesion molecules. Expression of E-selectin is induced on the cell surface of activated endothelial cells by key mediators of inflammation such as Il-1β and TNF-α (Bevilacqua et al, 1987) and has also been reported on the surface of tumour endothelial cells (Ye et al, 1995). Cell adhesion to E-selectin is mediated through the carbohydrate ligands sLX and sLA which are expressed predominantly on neutrophils (Phillips et al, 1990). In this way neutrophils can be recruited to sites of inflammation. However, sLX and sLA are known to also be expressed on a number of different tumour cell types and for many years this interaction has been implicated in the pathogenesis of cancer metastasis (Brodt et al, 1997; Dennis et al, 1982; Kitayama et al, 2000). SLX expression is increased in human hepatic colorectal metastases compared to the primary tumour (Hoff et al, 1989) and expression has been shown to correlate with poor survival of colorectal cancer patients (for example, in stage III patients 5 year survival was 42% in the sLX positive group vs 81% in patients with tumours negative for sLX in one study) (Nakamori et al, 1993). Expression of E-selectin on endothelial cells has also recently been shown to be essential in models of transendothelial migration of colon carcinoma cells (Laferriere et al, 2001).
Matsumoto et al (2002) have also retrospectively analyzed the patients in their previous study of cimetidine in colorectal cancer according to sLA and sLX expression. This was a small study the primary endpoints of which were originally to improve appetite and reduce oesophagitis, not prolong survival. In addition, it has not been analyzed on an intention to treat basis (10% of patients were excluded from analysis). The results, however, are striking and do appear to justify further investigation of the effect of cimetidine on E-selectin expression and the consequences of this interaction on sLA and sLX expressing colonic carcinoma.
In summary, there appears to be beneficial effects of cimetidine on colorectal cancer. There is some evidence for immunological mechanisms and for effects on E-selectin mediated adhesion. Further large-scale clinical trials appear warranted.
References
Adams WJ, Lawson JA, Morris DL (1994a) Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut 35: 1632–1636
Adams WJ, Morris DL (1994) Short-course cimetidine and survival with colorectal cancer. Lancet 344: 1768–1769
Adams WJ, Morris DL (1997) Pilot study – cimetidine enhances lymphocyte infiltration of human colorectal carcinoma: results of a small randomized control trial. Cancer 80: 15–21
Adams WJ, Morris DL, Ross WB, Lubowski DZ, King DW, Peters L (1994b) Cimetidine preserves non-specific immune function after colonic resection for cancer. Aust NZ J Surg 64: 847–852
Armitage JO, Sidner RD (1979) Antitumour effect of cimetidine. Lancet 1: 882–883
Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone Jr MA (1987) Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 84: 9238–9242
Brodt P, Fallavollita L, Bresalier RS, Meterissian S, Norton CR, Wolitzky BA (1997) Liver endothelial E-selectin mediates carcinoma cell adhesion and promotes liver metastasis. Int J Cancer 71: 612–619
Creagan ET, Ahmann DL, Green SJ, Long HJ, Frytak S, Itri LM (1985) Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanoma. J Clin Oncol 3: 977–981
Dennis J, Waller C, Timpl R, Schrirrmacher V (1982) Surface sialic acid reduces attachment of metastatic tumour cells to collagen type IV and fibronectin. Nature 300: 274–276
Garcia-Caballero M, Nunezed X, Castro I, Kusche J, Vora-Thorbeck L (1993) Histamine metabolism in human breast and colorectal cancer: Its effect on other host tissues. Adv Biosci 89: 273–287
Harrison JC, Dean PJ, el-Zeky F, Vander Zwaag R (1994) From Dukes through Jass: pathological prognostic indicators in rectal cancer. Hum Pathol 25: 498–505
Hoff SD, Matsushita Y, Ota DM, Cleary KR, Yamori T, Hakomori S, Irimura T (1989) Increased expression of sialyl-dimeric LeX antigen in liver metastases of human colorectal carcinoma. Cancer Res 49: 6883–6888
Jutel M, Watanabe T, Klunker S, Akdis M, Thomet OA, Malolepszy J, Zak-Nejmark T, Koga R, Kobayashi T, Blaser K, Akdis CA (2001) Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 413: 420–425
Kelly MD, King J, Cherian M, Dwerryhouse SJ, Finlay IG, Adams WJ, King DW, Lubowski DZ, Morris DL (1999) Randomized trial of preoperative cimetidine in patients with colorectal carcinomas with quantitative assessment of tumor-associated lymphocytes. Cancer 85: 1658–1663
Kitayama J, Tsuno N, Sunami E, Osada T, Muto T, Nagawa H (2000) E-selectin can mediate the arrest type of adhesion of colon cancer cells under physiological shear flow. Eur J Cancer 36: 121–127
Kobayashi K, Matsumoto S, Morishima T, Kawabe T, Okamoto T (2000) Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression. Cancer Res 60: 3978–3984
Laferriere J, Houle F, Taher MM, Valerie K, Huot J (2001) Transendothelial migration of colon carcinoma cells requires expression of E-selectin by endothelial cells and activation of stress-activated protein kinase-2 (SAPK/p38) in the tumour cells. J Biol Chem 276: 33762–33772
Langman MJ, Dunn JA, Whiting JL, Burton A, Hallissey MT, Fielding JW, Kerr DJ (1999) Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer. British Stomach Cancer Group. Br J Cancer 81: 1356–1362
Lawson JA, Adams WJ, Morris DL (1996) Ranitidine and cimetidine differ in their in vitro and in vivo effects on human colonic cancer growth. Br J Cancer 73: 872–876
Links M, Clingan PR, Phadke K, O'Baugh J, Legge J, Adams WJ, Ross WB, Morris DL (1995) A randomized trial of cimetidine with 5-florouracil and folinic acid in metastatic colorectal cancer. Eur J Surg Oncol 21: 523–525
Matsumoto S (1995) Cimetidine and survival with colorectal cancer. Lancet 346: 115
Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Okamoto T (2002) Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. Br J Cancer 86: 161–167
Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, Kabuto T, Iwanaga T, Matsushita Y, Irimura T (1993) Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 53: 3632–3637
Nielsen H, Mcardle C, Moesgaard F (1998) The effect of ranitidine on long term survival in primary colorectal cancer. A 40 months interim analysis. GI Cancer 2: 227–233
Phillips ML, Nudelman E, Gaeta FC, Perez M, Singhal AK, Hakomori S, Paulson JC (1990) ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex. Science 250: 1130–1132
Sagaster P, Micksche M, Flamm J, Ludwig H (1995) Randomised study using IFN-alpha versus IFN-alpha plus coumarin and cimetidine for treatment of advance renal cancer. Ann Oncol 6: 999–1003
Svendsen LB, Ross C, Knigge U, Frederiksen HJ, Graversen P, Kjaergard J, Luke M, Stimpel H, Sparso BH (1995) Cimetidine as an adjuvant treatment in colorectal cancer. A double-blind, randomized pilot study. Dis Colon Rectum 38: 514–518
Tonnesen H, Knigge U, Bulow S, Damm P, Fischermann K, Hesselfeldt P, Hjortrup A, Pedersen IK, Pedersen VM, Siemssen OJ, Svendsen LB, Christiannen PM (1988) Effect of cimetidine on survival after gastric cancer. Lancet 2: 990–992
Ye C, Kiriyama K, Mistuoka C, Kannagi R, Ito K, Watanabe T, Kondo K, Akiyama S, Takagi H (1995) Expression of E-selectin on endothelial cells of small veins in human colorectal cancer. Int J Cancer 61: 455–460
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Eaton, D., Hawkins, R. Cimetidine in colorectal cancer – are the effects immunological or adhesion-mediated?. Br J Cancer 86, 159–160 (2002). https://doi.org/10.1038/sj.bjc.6600097
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6600097
This article is cited by
-
Cimetidine attenuates vinorelbine-induced phlebitis in mice by militating E-selectin expression
Cancer Chemotherapy and Pharmacology (2014)